Shares of Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM – Get Free Report) fell 1.3% on Thursday . The company traded as low as $18.38 and last traded at $18.38. 1,048 shares traded hands during trading, a decline of 51% from the average session volume of 2,146 shares. The stock had previously closed at $18.62.
Amplify Treatments, Testing and Advancements ETF Stock Down 0.9 %
The stock has a market cap of $10.02 million, a price-to-earnings ratio of 7.10 and a beta of 1.08. The stock has a fifty day moving average of $18.57 and a two-hundred day moving average of $18.51.
Amplify Treatments, Testing and Advancements ETF Company Profile
The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.
Featured Articles
- Five stocks we like better than Amplify Treatments, Testing and Advancements ETF
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is a SEC Filing?
- MarketBeat Week in Review – 6/24 – 6/28
- The How and Why of Investing in Gold Stocks
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Amplify Treatments Testing and Advancements ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Treatments Testing and Advancements ETF and related companies with MarketBeat.com's FREE daily email newsletter.
